GHK-Cu

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-histidyl-lysine) whose plasma levels decline with age — a fact that anchors the anti-aging framing under which it is sold. Its reputation was built in dermatology, and that is where its evidence still lives: the joint claims are an extrapolation the published literature has never tested.

The mechanistic gap vendors skip

In dermal fibroblasts, GHK-Cu stimulates collagen synthesis at picomolar-to-nanomolar concentrations and increases glycosaminoglycan output. But look at which GAGs: predominantly dermatan and heparan sulfate — the skin-matrix molecules — not the chondroitin-sulfate-rich aggrecan that gives cartilage its compressive stiffness. The leap from skin-matrix stimulation to cartilage repair is asserted by vendors, not demonstrated anywhere in the literature.

The one joint study

In vivo, GHK-Cu injected into rat wound chambers increased collagen, DNA, and GAG accumulation concentration-dependently — the foundational wound-healing result behind its reputation. The single joint-adjacent study is a 2015 rat ACL-reconstruction model: weekly intra-articular GHK-Cu reduced knee laxity at 6 weeks (p=0.009) versus saline, but the difference disappeared by 12 weeks. That transient result has not been followed up in the decade since. One open question is whether the early benefit reflected wound-phase angiogenesis rather than any durable tissue improvement. There is no cartilage-defect, osteoarthritis, or tendon model at all.

The human evidence

For joints, tendon, or cartilage: none. No trial of GHK-Cu for any musculoskeletal indication has been published. The human literature is cosmetic dermatology — small facial-aging and wound studies of topical creams, summarized in reviews led by the peptide's discoverer and commercial advocate — reviews whose tone is closer to promotion than appraisal. Those results, whatever their merit for skin, say nothing about injected GHK-Cu and nothing about joints. Widely repeated claims that GHK "modulates ~4,000 genes" derive from in-silico expression screens, not clinical outcomes in any tissue.

Regulatory status

Injectable GHK-Cu is not FDA-approved for anything; what is sold online for injection is an unapproved gray-market product. GHK-Cu is not named on the WADA Prohibited List, but as a non-approved substance, injected use by athletes plausibly falls under the S0 catch-all.

Safety

Topical cosmetic use appears well tolerated. Systemic or injected safety in humans is essentially unstudied — no human parenteral dose has ever been validated — and copper-complex peptides raise theoretical concerns around copper handling at supraphysiologic exposure. Gray-market injectables add the usual identity, sterility, and dose-accuracy risks. The rat ACL study used 0.3–3 mg/mL intra-articularly; in-vitro effects occur at nanomolar concentrations. This entry is research appraisal, not dosing guidance.

What would change the picture

Replication or extension of the rat ACL finding with sustained endpoints, or any cartilage-tissue model — even a chondrocyte or explant study with functional matrix endpoints. Neither has appeared.